knowledge -WSS

knowledge

author：entertainment 2025-10-01 00:52:55 - browse：21

A crowd of miniature figurines facing towards an hourglass. -- cancer coverage from STAT — Adobe

It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.

There’s been a proliferation of various biological aging clocks, mathematical models that look at things like genetic markers or proteins in your body to make some estimation of an individual’s biological age. Research interest in using these clocks has exploded. In the last five years, thousands of papers on or incorporating the clocks have been published. The paper describing one popular biological aging clock, PhenoAge, has over 1,800 citations alone. One recent study suggested that a reason cancer incidence is increasing among younger adults may be accelerated aging, based on this particular clock.

But as scientists use these clocks to associate biological age with specific health risks, like cancer or dementia, and numerous companies eagerly offer biological age measurements in exchange for hundreds of bucks, it may be worth noting that experts don’t agree on what “biological age” actually is.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： WHO recommends second malaria vaccine

WSS

What we owe ALS patients — and why one company fell short

The biotech scorecard for Q4: 16 stock

6 solutions to address cancer drug shortages and others

Stop Congress from blocking public access to science

The stability of $0 premiums in Medicare Advantage

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Hepatitis C has a cure — but many Americans still lack access to it

What will Novo Nordisk's VC do with its influx of cash?

How one medical school became remarkably diverse

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

DIEP, the 'gold standard' of breast reconstruction, is under threat

Will an HIV vaccine ever be a reality?

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA rejects Alnylam's heart disease treatment over insufficient data

The cancer drug shortage isn’t new — and neither are the solutions

Health insurers' Q3 question: how much care are people getting?

focus

Some top drug companies are starting to take action on climate

Stop Congress from blocking public access to science

When women are denied an abortion, their children fare worse than peers

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

RSV injection headlines need to be accurate for good uptake

Histogen: Failed biotech offers rare public look inside

entertainment

focus

entertainment

focus